Re-irradiation for recurrent rectal cancer – a single-center experience. (3rd May 2020)

• Record Type: Journal Article
• Authors: Al-Haidari, Ghazwan; Skovlund, Eva; Undseth, Christine; Rekstad, Bernt Louni; Larsen, Stein Gunnar; Åsli, Linn Merete; Dueland, Svein; Malinen, Eirik; Guren, Marianne Grønlie
• Is Part Of: Acta oncologica. Volume 59:Number 5(2020)
• Page Start: 534
• Page End: 540
• Publication Date: 2020-05-03
• Subjects: Oncology -- Periodicals; Cancer -- Treatment -- Periodicals; 616.992
• DOI: 10.1080/0284186X.2020.1725111
• Languages: English
• ISSNs: 0284-186X

Abstract

Abstract: Background: There is no clear consensus on the use of re-irradiation (reRT) in the management of locally recurrent rectal cancer (LRRC). The aim of the present study was to investigate all reRT administered for rectal cancer at a large referral institution and to evaluate patient outcomes and toxicity. Material and methods: All patients with rectal cancer were identified who had received previous pelvic radiotherapy (RT) and underwent reRT during 2006–2016. Medical records and RT details of the primary tumor treatments and rectal cancer recurrence treatments were registered, including details on reRT, chemotherapy, surgery, adverse events, and long-term outcomes. Results: Of 77 patients who received ReRT, 67 had previously received pelvic RT for rectal cancer and were administered reRT for LRRC. Re-irradiation doses were 30.0–45.0 Gy, most often given as hyperfractionated RT in 1.2–1.5 Gy fractions twice daily with concomitant capecitabine. The median time since initial RT was 29 months (range, 13–174 months). Of 36 patients considered as potentially resectable, 20 underwent surgery for LRRC within 3 months after reRT. Operated patients had better 3-year overall survival (OS) (62%) compared to those who were not operated (16%; HR 0.32, p = .001). The median gross tumor volume (GTV) was 107 cm 3, and 3-year OS was significantly better in patients with GTV <107 cm 3 (44%) compared to patients with GTV ≥107 cm 3 (21%; HR 0.52, p = .03). Conclusion: Three-year survival was significantly better for patients who underwent surgery after reRT or who had small tumor volume. Prospective clinical trials are recommended for further improvements in patient selection, outcomes, and toxicity assessment.